Regeneron Shares Updates on its Ongoing FOP Research Program
Potentially Promising Treatment for FOP
We are pleased to share a few exciting updates on our ongoing work to help improve the lives of people with FOP.
Bipartisan Support
21st Century Cures Legislation Signed by President Obama
On December 7, the Senate followed the House of Representative's lead and signed the 21st Century Cures bill which is focused on developing treatments and cures for rare diseases; President Obama signed it on December 13.
Three new Clementia sites now open for Part B of the Phase 2 Open-label Extension Trial
Approval of 3 New Sites!
The participation of individuals living with FOP in clinical studies and trials is key to FOP drug development efforts.
Join the IFOPA and Clementia for an Important Webinar
Phase 2 Trial Webinar
We hope you’ll join us Wednesday, Nov. 30, 2016, 11 am to noon Eastern Time, for an important webinar presented by Clementia on the top-line results from the phase 2 trial of palovarotene for treatment of patients with fibrodysplasia ossificans progressiva.
Opportunity for New Patients to Enroll in Palovarotene Study
Please read Clementia's Clinical Program Announcement: Opportunity for New Adult and Older Adolescent Subjects to Enroll in Palovarotene Study. Click here.
Regeneron's Work in FOP
The International FOP Association is pleased to share the following news from Regeneron Pharmaceuticals
Regeneron is pleased to inform you that anti-Activin A antibody, REGN2477, is now in a clinical trial.
A Remarkable Record of Service – And An Important Transition
Thank you for your commitment!
Still active in the FOP community, Dr. Pignolo has a accepted a new position.
Next Step in Clementia's Clinical Program for FOP
Enrollment information and FAQs
The IFOPA is pleased to share the announcement and new FAQs from Clementia Pharmaceuticals regarding the palovarotene clinical trial.
Penn Animal Study Findings Announced
FOP Flare-Ups
The IFOPA is pleased to share the press release and editorial from the Perelman School of Medicine at the University of Pennsylvania about their Animal Study Findings on FOP Flare-Ups and Low Oxygen.
FOP study conducted by researchers at Penn Medicine and CHOP
Results Announced
The IFOPA is pleased to share these announcements from the Perelman School of Medicine/University of Pennsylvania Health System and Clementia Pharmaceuticals sharing results of a study conducted by researchers at Penn Medicine and Children’s Hospital of Philadelphia (CHOP) on the effects of palovarotene in an animal model of Fibrodysplasia Ossificans Progressiva (FOP).
